FRINK Linked Data Fragments server

Matches in Wikidata for { <http://www.wikidata.org/entity/Q37864722> ?p ?o ?g. }

• Q37864722 description "article científic" @default.
• Q37864722 description "article scientifique" @default.
• Q37864722 description "articolo scientifico" @default.
• Q37864722 description "artigo científico" @default.
• Q37864722 description "artículu científicu espublizáu n'abril de 2011" @default.
• Q37864722 description "bilimsel makale" @default.
• Q37864722 description "scientific article published on 13 April 2011" @default.
• Q37864722 description "vedecký článok" @default.
• Q37864722 description "vetenskaplig artikel" @default.
• Q37864722 description "videnskabelig artikel" @default.
• Q37864722 description "vědecký článek" @default.
• Q37864722 description "wetenschappelijk artikel" @default.
• Q37864722 description "wissenschaftlicher Artikel" @default.
• Q37864722 description "наукова стаття, опублікована у квітні 2011" @default.
• Q37864722 description "научни чланак" @default.
• Q37864722 description "مقالة علمية نشرت في 13 أبريل 2011" @default.
• Q37864722 name "Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy" @default.
• Q37864722 name "Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy" @default.
• Q37864722 type Item @default.
• Q37864722 label "Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy" @default.
• Q37864722 label "Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy" @default.
• Q37864722 prefLabel "Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy" @default.
• Q37864722 prefLabel "Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy" @default.
• Q37864722 P1433 Q37864722-FB84D618-0EA8-4EB6-AB8E-B6618FEEFE76 @default.
• Q37864722 P1476 Q37864722-AAD417E2-DF7B-479F-8451-BA6215651D42 @default.
• Q37864722 P2093 Q37864722-16E261A4-793E-4788-B050-C0E54F518E76 @default.
• Q37864722 P2093 Q37864722-5DBDDBCA-B2E3-4E91-9B8C-CC447D704C79 @default.
• Q37864722 P2093 Q37864722-E314D127-2903-4382-8D1A-399F7707907C @default.
• Q37864722 P2860 Q37864722-011DDFA3-10A8-44D1-8EC4-67B63268ADF4 @default.
• Q37864722 P2860 Q37864722-02C2BD4B-EB42-4D4B-8749-E5836877023F @default.
• Q37864722 P2860 Q37864722-08EFB95D-1E52-4C7C-90FC-51A376FCABDD @default.
• Q37864722 P2860 Q37864722-0C86C810-61BD-40B1-ABB4-6040FAA32734 @default.
• Q37864722 P2860 Q37864722-0F6E417F-626B-41D3-ADBD-370A95E08CA0 @default.
• Q37864722 P2860 Q37864722-16609E9D-8CFA-43F7-A828-1EA8F8260509 @default.
• Q37864722 P2860 Q37864722-2115BC6B-CBD6-4492-A082-A8487B39D966 @default.
• Q37864722 P2860 Q37864722-28EDCCA6-329D-4316-A3F1-2DF09DEDBCA9 @default.
• Q37864722 P2860 Q37864722-314D9AA1-5CA0-4FA4-ACAB-457994B5A0E4 @default.
• Q37864722 P2860 Q37864722-3BC08CE7-D7DC-4D2F-B099-C71403673B4D @default.
• Q37864722 P2860 Q37864722-4BBFFFBD-8AB6-4197-ACF0-BC834173DCE7 @default.
• Q37864722 P2860 Q37864722-4C490DE8-9D55-4A52-85D9-DA97DFB1C009 @default.
• Q37864722 P2860 Q37864722-4F71B8E3-1B67-4CC3-A262-9AB3DE0647FB @default.
• Q37864722 P2860 Q37864722-5A536C98-4BE6-4C59-B554-AF9612E89708 @default.
• Q37864722 P2860 Q37864722-70FB2998-DE6D-488B-9994-4182D51FDF8E @default.
• Q37864722 P2860 Q37864722-7AAF5C5B-82D4-47D3-BAC9-493EF8621259 @default.
• Q37864722 P2860 Q37864722-80A98E2F-C67A-4563-9848-A2BA361DD990 @default.
• Q37864722 P2860 Q37864722-8FDFB5A7-4D1D-4A2F-89FE-5691015E6762 @default.
• Q37864722 P2860 Q37864722-93BE95DD-6E00-4568-9A9F-DDA6208E62EA @default.
• Q37864722 P2860 Q37864722-97A8CAB9-8606-4713-A878-49E0CA8E2338 @default.
• Q37864722 P2860 Q37864722-9AB1CA83-34D3-4CBD-BB67-270784CD9FA9 @default.
• Q37864722 P2860 Q37864722-9B52075C-5BE0-4B6B-AC05-5A9C63F5099A @default.
• Q37864722 P2860 Q37864722-AE05C4D0-B738-4948-87EB-A11F2C60AEA0 @default.
• Q37864722 P2860 Q37864722-B66FCB27-997B-4CE7-B53F-31BE910CE67B @default.
• Q37864722 P2860 Q37864722-CBD4E8E8-191B-4DA1-9A8F-0D5333D6285F @default.
• Q37864722 P2860 Q37864722-CC1F8B17-9EF4-44FB-B7E9-11C959DBCA6C @default.
• Q37864722 P2860 Q37864722-D7E0F10E-208E-448F-8A72-3E0BBA907BA5 @default.
• Q37864722 P2860 Q37864722-DE60F78D-8846-4B50-B35A-91F1C4914340 @default.
• Q37864722 P2860 Q37864722-E159B478-1181-45D6-B3EA-109DF856BDF5 @default.
• Q37864722 P2860 Q37864722-E2A6ABC8-CE30-4515-A285-14FA703AC5FA @default.
• Q37864722 P2860 Q37864722-E53D0FE7-5A58-4049-891B-F5568E18B76D @default.
• Q37864722 P2860 Q37864722-E58AC783-0A91-460F-BF77-313254496B23 @default.
• Q37864722 P2860 Q37864722-EA4527C1-133C-4A4C-9AA5-2443E14B10F1 @default.
• Q37864722 P2860 Q37864722-EEBD15AC-F9D2-4118-A5E1-360EE2485B5B @default.
• Q37864722 P2860 Q37864722-EF9594AB-F1B0-41F9-85BB-2CA99D6D67AA @default.
• Q37864722 P2860 Q37864722-F2EE1C26-25AA-48A0-90B5-41B1B075EA86 @default.
• Q37864722 P2860 Q37864722-F3D277AE-8C87-4E63-AED7-5CB38576ADBD @default.
• Q37864722 P2860 Q37864722-F8406A89-12AC-42D1-B281-17A71E12BD64 @default.
• Q37864722 P2860 Q37864722-FA697211-75CC-4AC3-871B-CBFE168E3C26 @default.
• Q37864722 P304 Q37864722-8934F5A9-7BAE-4BEE-82E1-569F4A476D46 @default.
• Q37864722 P31 Q37864722-98831851-4d44-4c4c-a1e0-8fa836a9203c @default.
• Q37864722 P31 Q37864722-EBCB45C4-531C-4892-A5E6-DEAE81C6503B @default.
• Q37864722 P356 Q37864722-F7AFD058-AE8E-4E0C-ACB2-FE51E2F42FDA @default.
• Q37864722 P433 Q37864722-37D174E6-9F11-4EDE-81A5-55B8C20BA058 @default.
• Q37864722 P478 Q37864722-569D034D-A440-4FEE-B05A-D854B363AB35 @default.
• Q37864722 P50 Q37864722-804786D7-A17F-4FFE-BFBE-41FF1ACA7E71 @default.
• Q37864722 P50 Q37864722-8960E11B-1C45-4AFA-8706-514A0B044135 @default.
• Q37864722 P50 Q37864722-E01E47E4-ED25-4F56-8B50-57D849113912 @default.
• Q37864722 P577 Q37864722-0A0E50B6-F306-4EF9-AF83-0F8DC05BDE1B @default.
• Q37864722 P698 Q37864722-B3D51EB7-9A04-4835-BBD5-293516647878 @default.
• Q37864722 P921 Q37864722-60519BC6-A885-42D6-9576-FCF2A2E5AE42 @default.
• Q37864722 P356 J.1464-410X.2010.10039.X @default.
• Q37864722 P698 21489116 @default.
• Q37864722 P1433 Q4835773 @default.
• Q37864722 P1476 "Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy" @default.
• Q37864722 P2093 "Thomas J Polascik" @default.
• Q37864722 P2093 "Thomas M Wheeler" @default.
• Q37864722 P2093 "Vladimir Mouraviev" @default.
• Q37864722 P2860 Q24650647 @default.
• Q37864722 P2860 Q33184251 @default.
• Q37864722 P2860 Q33557496 @default.
• Q37864722 P2860 Q33730189 @default.
• Q37864722 P2860 Q33853025 @default.
• Q37864722 P2860 Q34380870 @default.
• Q37864722 P2860 Q34658404 @default.
• Q37864722 P2860 Q35649908 @default.
• Q37864722 P2860 Q35963464 @default.
• Q37864722 P2860 Q36225932 @default.
• Q37864722 P2860 Q36836075 @default.
• Q37864722 P2860 Q37016855 @default.
• Q37864722 P2860 Q37041973 @default.
• Q37864722 P2860 Q37054328 @default.

• next